Freeze and boost: new combo aims to stop breast cancer return
NCT ID NCT03546686
First seen Oct 01, 2025 · Last updated Jun 20, 2026 · Updated 32 times
Summary
This phase 2 trial is testing whether combining immunotherapy drugs (pembrolizumab, ipilimumab, nivolumab) with a freezing technique called cryoablation before standard surgery can improve outcomes for women with triple-negative breast cancer. The study enrolls 51 women who have residual disease after initial chemotherapy. The goal is to see if this approach extends the time without cancer returning or spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cedars Sinai Medical Center
Los Angeles, California, 90048, United States
-
Ohio State University Medical Center
Columbus, Ohio, 43210, United States
-
Providence Cancer Institute
Portland, Oregon, 97213, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pembrolizumab, Ipilimumab, Nivolumab (immunotherapy drugs)
What this could lead to
If successful, this approach could reduce the risk of breast cancer returning after surgery and improve long-term survival for women with triple-negative breast cancer.
What could go wrong
This is a small, early-phase trial with only 51 participants, so results may not apply to all patients. Immunotherapy can cause serious side effects like inflammation of organs, and the combination with cryoablation is experimental.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.